Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

This study tests semaglutide (a weekly injection medication used for type 2 diabetes and obesity) in obese children and teenagers who have prediabetes, new-onset type 2 diabetes, and fatty liver disease (NAFLD). The goal is to see if semaglutide improves liver fat, blood sugar control, and metabolic health in this young population. **You may be eligible if...** - You are aged 10–20 with obesity (BMI ≥ 85th percentile) and have prediabetes or new-onset type 2 diabetes (diagnosed within 24 months) - You have fatty liver disease with ≥ 8% liver fat on imaging - You weigh at least 54 kg and are in puberty (Tanner stage II–IV) - If on metformin, you have been on a stable dose for up to 12 months **You may NOT be eligible if...** - Your type 2 diabetes has been present for more than 24 months - You have kidney problems, elevated enzymes, or are otherwise not in good general health - You are pregnant or may become pregnant during the study Talk to your doctor to see if this trial is right for you.